August 9, 2024

EVerMed Inc. has raised 280 million yen in the 1st close of its seed round

EVerMed Inc. has raised a total of 280 million yen through a third-party allotment of new shares to WUV 1 Limited Partnership (Shinjuku-ku, Tokyo; operating company: Waseda University Ventures, Inc.; CEO: Tetsuya Yamamoto) and San-Ai Corporation (Minato-ku, Tokyo; CEO: Masami Miura).

EVerMed is a startup company originating from the Jikei University School of Medicine that aims to apply extracellular vesicles to medical applications, and will use the funds raised this time to accelerate the development of extracellular vesicle medicines.

Categories: News